Supplementary Figure 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
Supplementary Fig. 3 shows Differentially Expressed Gene Signatures (DEGs) based on next-gene sequencing (mRNA sequencing) for ARLow/mCRPC/NEPC (PC-3DU145), ARLow/mCSPC/NEPC taxane resistant (DUTXR and PC-3TXR) PCa cell lines. IPA predicted key pathways based on DEGs between Taxane resistant and sensitivity. Fig. 3A. Differentially expressed gene Signature was identified among DEGs for ARLow/mCRPC/NEPC (PC-3DU145), ARLow/mCSPC/NEPC taxane-resistant (DUTXR and PC-3TXR) PCa cell lines. Venn diagrams represent unique and common DEGs for ARLow/mCRPC/NEPC (PC-3, DU145), and ARLow/mCSPC/NEPCtaxane-resistant (DUTXR and PC-3TXR) cell lines. Fig. 3B. IPA predicted key pathways based on DEGs between Taxane resistant and sensitivity. Cluster 2 (IPA predicted activation of PPARA), Cluster 4 (ERK/MAPK signaling, MSP-RON Signaling, upregulation of FOXM1, ESR1, CEBPB, XBP1, and NPM1), Cluster 6 (ATM signaling, and MYC).